Clinical trials: Stroke, Acute Cerebral Infarction
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Ischemic Stroke, Stroke
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a medium dose of IV rt-PA plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome…
- Conditions
- Ischemic Stroke, Stroke, Brain Infarction
- Trial name
- CLEAR-ER (NCT00894803)
- Testing
- Eptifibatide, rt-PA
- Where
- 20 sites in United States
- Volunteers
- 126 people
- Sponsor
- University of Cincinnati
Influenza, Pneumonia
Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age.
- Conditions
- Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction
- Trial name
- NCT03694392
- Testing
- Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
- Where
- United States
- Volunteers
- 2,776,278 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Acute Ischemic Stroke
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) natalizumab reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) in participants with acute…
- Trial name
- ACTION (NCT01955707)
- Testing
- natalizumab
- Where
- 50 sites in United States, Germany and 1 more
- Volunteers
- 161 people
- Sponsor
- Biogen
Acute Stroke, Brain Ischemia
The Capillary Index Score Trial
This study seeks to investigate the capillary index score (CIS) to further improve patient selection of endovascular treatment (EVT) in acute ischemic stroke (AIS).
- Conditions
- Acute Stroke, Brain Ischemia, Ischemic Stroke
- Trial name
- NCT02618031
- Testing
- Endovascular Treatment (EVT)
- Where
- 6 sites in United States
- Volunteers
- 57 people
- Sponsor
- Firas Al-Ali